INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $98,650,178 | -23.7% | 1,893,841 | -7.2% | 0.04% | -20.8% |
| Q2 2023 | $129,223,583 | +19.1% | 2,040,802 | +1.9% | 0.05% | +15.2% |
| Q1 2023 | $108,465,158 | +1.8% | 2,003,050 | -0.5% | 0.05% | -4.2% |
| Q4 2022 | $106,567,491 | +4.1% | 2,013,747 | -8.5% | 0.05% | -4.0% |
| Q3 2022 | $102,385,000 | -15.1% | 2,200,408 | +4.2% | 0.05% | -9.1% |
| Q2 2022 | $120,586,000 | +1980.9% | 2,112,587 | +2130.6% | 0.06% | +2650.0% |
| Q1 2022 | $5,795,000 | +24.0% | 94,710 | +6.0% | 0.00% | 0.0% |
| Q4 2021 | $4,674,000 | +40.4% | 89,310 | 0.0% | 0.00% | +100.0% |
| Q3 2021 | $3,329,000 | -10.0% | 89,310 | -1.4% | 0.00% | 0.0% |
| Q2 2021 | $3,699,000 | +13.8% | 90,610 | -5.4% | 0.00% | 0.0% |
| Q1 2021 | $3,251,000 | +8.0% | 95,810 | +1.3% | 0.00% | 0.0% |
| Q4 2020 | $3,009,000 | +23.9% | 94,610 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $2,428,000 | +7.2% | 94,610 | +7.3% | 0.00% | 0.0% |
| Q2 2020 | $2,264,000 | +108.7% | 88,210 | +24.9% | 0.00% | 0.0% |
| Q1 2020 | $1,085,000 | -56.4% | 70,610 | -2.8% | 0.00% | 0.0% |
| Q4 2019 | $2,491,000 | +315.9% | 72,610 | -9.5% | 0.00% | – |
| Q3 2019 | $599,000 | -34.1% | 80,210 | +14.6% | 0.00% | -100.0% |
| Q2 2019 | $909,000 | +1.6% | 70,010 | -4.8% | 0.00% | 0.0% |
| Q1 2019 | $895,000 | +6.9% | 73,510 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $837,000 | -47.5% | 73,510 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $1,595,000 | +22.8% | 73,510 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,299,000 | +37.5% | 73,510 | +63.7% | 0.00% | 0.0% |
| Q1 2018 | $945,000 | +45.4% | 44,910 | 0.0% | 0.00% | – |
| Q4 2017 | $650,000 | -17.5% | 44,910 | -10.0% | 0.00% | -100.0% |
| Q3 2017 | $788,000 | +21.0% | 49,910 | -4.8% | 0.00% | 0.0% |
| Q2 2017 | $651,000 | -27.7% | 52,410 | -5.4% | 0.00% | 0.0% |
| Q1 2017 | $900,000 | +7.7% | 55,410 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $836,000 | -0.9% | 55,410 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $844,000 | -60.8% | 55,410 | 0.0% | 0.00% | -50.0% |
| Q2 2016 | $2,151,000 | +147.8% | 55,410 | +77.5% | 0.00% | +100.0% |
| Q1 2016 | $868,000 | -48.3% | 31,210 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $1,679,000 | +34.3% | 31,210 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $1,250,000 | +15.1% | 31,210 | -8.2% | 0.00% | 0.0% |
| Q2 2015 | $1,086,000 | +954.4% | 34,000 | +690.7% | 0.00% | – |
| Q1 2015 | $103,000 | +312.0% | 4,300 | +207.1% | 0.00% | – |
| Q4 2014 | $25,000 | +8.7% | 1,400 | -17.6% | 0.00% | – |
| Q3 2014 | $23,000 | -42.5% | 1,700 | -29.2% | 0.00% | – |
| Q2 2014 | $40,000 | – | 2,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |